Heron Therapeutics (HRTX) in Focus: Stock Gains 7.5% – Tale of the Tape

Zacks

Heron Therapeutics, Inc. (HRTX) was a big mover last session with its shares rising over 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has gained over 22% since June 9.

This specialty pharmaceutical company has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate hasn’t been in trend either. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Heron Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is positive.

Investors interested in the Med-Drugs industry may consider better-ranked stocks like Aeolus Pharmaceuticals Inc. (AOLS), Ariad Pharmaceuticals Inc. (ARIA) and Aerie Pharmaceuticals, Inc. (AERI). All the three stocks hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply